Inclusion Criteria:
* Male participants aged 18-55 years inclusive at ICF signing.
* At screening, weight ≥50.0 kg and BMI 19.0-28.0 kg/m² inclusive.
* Male participants must agree to use reliable contraception for themselves and their partners during the study and for 1 year after dosing (see Appendix 2), and not donate sperm for assisted reproduction.
* Able to understand the study procedures and methods, voluntarily sign the ICF, and willing to strictly comply with the protocol and complete the study.
* Detailed medical history, physical examination, vital signs, laboratory tests \[CBC, blood chemistry, coagulation, urinalysis, stool routine and occult blood, thyroid function (FT3, FT4, TSH), HbA1c, amylase, lipase, serum calcitonin\], 12-lead ECG, chest X-ray (PA), digital rectal examination, and abdominal ultrasound (liver, gallbladder, pancreas, spleen, both kidneys) show no abnormalities or no clinically significant abnormalities.
Exclusion Criteria:
* History or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or MEN2; or serum calcitonin ≥50 ng/L at screening.
* History of chronic pancreatitis, or acute pancreatitis within 3 months before ICF signing.
* History of acute gallbladder disease within 3 months before ICF signing.
* Any malignancy within 5 years before ICF signing (except basal cell carcinoma treated with curative therapy and considered cured).
* History of serious cardiovascular, neuropsychiatric, gastrointestinal, respiratory, urinary, or endocrine disease within 1 year before ICF signing (e.g., acute myocardial infarction, major depression, gastric ulcer, uremia).
* As judged by the investigator, dysphagia at screening, or concurrent conditions that may affect drug absorption, distribution, metabolism, or excretion, such as active inflammatory bowel disease, gastrectomy, or any intestinal resection.
* Severe hypoglycemia within 3 months before screening.
* History of allergic diseases (e.g., asthma, urticaria, eczematous dermatitis), or known intolerance or allergy to GLP-1R agonists.
* Hemorrhoids, or perianal disease with regular/current hematochezia, irritable bowel syndrome, or inflammatory bowel disease.
* Habitual constipation or diarrhea.
* Blood donation or major bleeding (≥400 mL) within 3 months before screening, or between screening and first dose.
* History of drug abuse within 3 years before screening (e.g., morphine, ketamine, THC acid, methamphetamine, MDA, cocaine), or positive urine drug test at screening (D-2).
* Smoking \>5 cigarettes/day or habitual use of nicotine-containing products within 3 months before screening, and unable to abstain during the study.
* History of alcohol abuse within 1 year before screening (male: \>14 standard units/week; 1 unit = 14 g alcohol, e.g., 360 mL beer, 45 mL 40% spirits, or 150 mL wine), or positive alcohol breath/blood test at screening.
* Special dietary requirements and unable to accept the standardized diet.
* Habitual intake of grapefruit juice or excessive tea, coffee, and/or caffeinated beverages (\>8 cups, 1 cup = 250 mL) within 3 months before screening, and unable to abstain during the study.
* Unable to avoid strenuous exercise or other behaviors that may affect PK parameters from 48 h before dosing through the entire study.
* History of needle or blood phobia, difficult blood collection, or intolerance to venipuncture.
* Use of any medication within 28 days or 5 elimination half-lives before first dose, whichever is longer, including prescription drugs, OTC drugs, herbal medicines, Chinese patent medicines, or nutritional supplements.
* Live vaccination within 1 month before screening, or planned vaccination during the study.
* Participation in any clinical trial within 3 months before screening (except ICF signing only without drug/device intervention), or last dose of investigational drug \<5 half-lives before screening.
* Occupational long-term radiation exposure; or significant radiation exposure within 1 year before the study (e.g., ≥2 chest/abdominal CT scans or ≥3 other types of X-ray examinations); or planned radiological diagnosis/treatment within 1 year after the study; or participation in a clinical trial involving radiolabeled drugs within 1 year.
* Any other condition that, in the investigator's opinion, makes the participant unsuitable for the trial.
